Physicians

This guideline provides recommendations for HIV care teams on implementing long-acting injectable HIV treatment, including cabotegravir and rilpivirine. 

This journal examines the role of circular RNAs (circRNAs) in HIV-1 replication, highlighting the discovery that backsplicing of the HIV-1 transcript produces multiple circRNAs that enhance viral replication. 

This journal presents findings from a pilot randomized clinical trial evaluating two brief interventions aimed at increasing HIV pre-exposure prophylaxis (PrEP) uptake among rural people who inject drugs (PWID) attending syringe services programs (SSPs) in Kentucky. 

This fact sheet provides a detailed comparison of tuberculosis (TB) treatment regimens, encompassing both drug-sensitive and drug-resistant TB. 

This journal discusses the integration of hepatitis C management into primary care as a key strategy for eliminating the disease. It examines barriers to care, the role of direct-acting antivirals, and the importance of screening and treatment within primary care settings.

This journal examines the clinical course of autoimmune hepatitis (AIH) in Hispanic and African American patients at a South Bronx hospital. The findings contribute to a better understanding of AIH in diverse racial and ethnic groups, emphasizing the need for tailored healthcare strategies.

This journal compares the effectiveness of Heplisav-B and standard hepatitis B vaccines as boosters for healthcare workers with low immunity to hepatitis B, measured by anti-HBs antibody levels. Results show that Heplisav-B offers a significantly higher seropositivity rate (99.4%) compared to the standard vaccine (92.7%).

This journal outlines best practices for engaging communities affected by chronic hepatitis B, emphasizing the importance of involving individuals with lived experiences in public health initiatives to improve diagnosis and treatment outcomes.

This journal evaluates the Oregon HOPE TeleHCV study, a peer-facilitated telemedicine model (Peer TeleHCV) for hepatitis C virus (HCV) treatment among people who use drugs (PWUD) in rural Oregon. The findings highlight high patient satisfaction and key factors that enhanced implementation, demonstrating the model’s potential to reduce barriers and improve treatment access.

This webpage explores the risks of untreated hepatitis C, highlighting its potential to cause severe liver damage, cirrhosis, liver failure, and even liver cancer. Beyond liver-related issues, the virus can also contribute to complications such as fatigue, joint pain, kidney disease, and diabetes. Early diagnosis and treatment are essential to preventing these long-term health risks and improving overall well-being.